7/15/88-7/31/15 Coordinating Center, Studies of Ocular Complications of AIDS. PI: Curtis L. Meinart' Role: Deputy Director, Medical Ophthalmologist, Epidemiologist; Major Goal: To evaluate vision outcomes among patients with AIDS and with ocular opportunistic infections secondary to AIDS, most commonly cytomegalovirus retinitis.
7/1/03-12/31/17 Coordinating Center, Multicenter Uveitis Steroid Treatment (MUST) Trial. PI: Janet T. Holbrook. Role: Medical Officer; Chair, Medical Therapy Quality Assurance Committee; Major Goal: Compare the fluocinolone acetonide implant to “standard therapy” for the treatment of patients with severe, vision-threatening intermediate, posterior, or panuveitis.
10/1/10-8/31/15 Systemic Immunosuppressive Therapy for Eye Disease (SITE) 2 Cohort Study. PI: John H. Kempen. Role: Principal Investigator at the Johns Hopkins Site, Major Goal: Evaluate the long-term risk of cancer diagnosis and cancer-related morbidity in patients receiving immunosuppressive therapy for non-infectious inflammatory eye diseases.
7/1/11-6/30/16 North American AIDS Cohorts Collaboration on Research and Design. PI: Richard D. Moore. Consortium HIV/AIDS databases from academic medical centers and community based facilities that deliver HIV care in the U.S. and Canada to identify questions of intraregional and interregional importance that are critical to the contemporary treatment of HIV infection in North America, and design and implement the analyses necessary to answer these questions.
10/1/12-9/30/16 A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab as Maintenance Therapy in Subjects Requiring High Doses of Corticosteroids for Active Non-Infectious Intermediate, Posterior, and Pan-Uveitis. PI: Jennifer E. Thorne
10/1/12-9/30/16 A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects with Non-Infectious Intermediate, Posterior, and Pan-Uveitis. PI: Jennifer E. Thorne
10/1/12-9/30/16 A Multicenter Open-Label Study of the Long-Term Safety and Efficacy of the Human Anti-TNF Monocloncal Antibody in Subjects with Non-Infectious, Intermediate, Posterior, and Pan-Uveitis. PI: Jennifer E. Thorne
12/1/12-11/30/16 A Randomized, Double masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Active Non-Infectious Intermediate, Posterior, or Pan Uveitis. PI: Jennifer E. Thorne
12/1/12-11/30/16 A Randomized, Double masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Subjects with Non-Infectious Intermediate, Posterior, or Pan-Uveitis currently Inactive. PI: Jennifer E. Thorne
10/1/13-9/30/17 Proof of Concept Study of the Effectiveness of Ozurdex in lieu of Oral Corticosteroids for the Control of Active Intermediate, Posterior and Panuveitis Requiring Immunosuppressive Drug Therapy. PI: Jennifer E. Thorne.
View all on PubMed
Direct and indirect resource use, healthcare costs and work force absence in patients with non-infectious intermediate, posterior or panuveitis. Thorne JE, Skup M, Tundia N, Macaulay D, Revol C, Chao J, Joshi A, Dick AD. Acta Ophthalmol. 2016 Mar 2. doi: 10.1111/aos.12987. [Epub ahead of print]
Autoimmune bullous diseases with skin and eye involvement: Cicatricial pemphigoid, pemphigus vulgaris, and pemphigus paraneoplastica. Broussard KC, Leung TG, Moradi A, Thorne JE, Fine JD. Clin Dermatol. 2016 Mar-Apr;34(2):205-13. doi: 10.1016/j.clindermatol.2015.11.006. Epub 2015 Dec 19.
Using a patient-centered approach to benefit-harm assessment in treatment decision-making: a case study in uveitis. Yu T, Holbrook JT, Thorne JE, Puhan MA. Pharmacoepidemiol Drug Saf. 2016 Jan 22. doi: 10.1002/pds.3959. [Epub ahead of print]
Remission of Intermediate Uveitis: Incidence and Predictive Factors. Kempen JH, Gewaily DY, Newcomb CW, Liesegang TL, Kaçmaz RO, Levy-Clarke GA, Nussenblatt RB, Rosenbaum JT, Sen HN, Suhler EB, Thorne JE, Foster CS, Jabs DA, Payal A, Fitzgerald TD; Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Research Group. Am J Ophthalmol. 2016 Jan 6. pii: S0002-9394(16)30002-2. doi: 10.1016/j.ajo.2015.12.034. [Epub ahead of print]
Dissociations of the Fluocinolone Acetonide Implant: The Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study. Holbrook JT, Sugar EA, Burke AE, Vitale AT, Thorne JE, Davis J, Jabs DA; Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group. Am J Ophthalmol. 2015 Dec 31. pii: S0002-9394(15)30049-0. doi: 10.1016/j.ajo.2015.12.028. [Epub ahead of print]